EyePoint announces $175M common stock offering

EyePoint Pharmaceuticals announced that it has commenced an underwritten public offering of $175M of shares of its common stock. All of the shares are being offered by EyePoint. EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of EYP-1901 for wet age related macular degeneration through the initiation of and reporting of topline data from two pivotal Phase 3 clinical trials, as well as support its earlier stage pipeline development initiatives, and for general corporate purposes. J.P. Morgan, TD Cowen and Guggenheim Securities are acting as joint book running managers for the offering.